Page last updated: 2024-10-24

regulation of heart morphogenesis

Definition

Target type: biologicalprocess

Any process that modulates the frequency, rate or extent of heart morphogenesis. [GOC:BHF]

Heart morphogenesis, the intricate process of shaping the heart from a simple tube into a complex, four-chambered organ, is tightly regulated by a complex interplay of genetic and environmental factors. This intricate orchestration involves precise control of cell proliferation, differentiation, migration, and apoptosis, ensuring proper development of the heart chambers, valves, and surrounding structures.

The process begins with the specification of the cardiac progenitor cells, which commit to a cardiac fate. This involves the expression of key transcription factors, including Nkx2.5, GATA4, and MEF2C, which regulate the expression of downstream target genes essential for heart development. These early events lay the foundation for subsequent heart morphogenesis, setting the stage for the formation of the heart tube.

As the heart tube forms, it undergoes a series of coordinated morphogenetic movements, including looping and chamber formation. This intricate choreography is driven by a combination of intrinsic cellular cues and external signals, such as retinoic acid and fibroblast growth factors. These signaling pathways act in concert to orchestrate the precise arrangement and differentiation of cardiac cells, ensuring the proper development of the heart chambers.

The heart tube elongates and folds into a characteristic S-shape, a process known as looping. This looping is critical for the proper positioning of the heart within the thorax and for the subsequent separation of the heart into distinct chambers. Simultaneously, the heart tube begins to divide into the four chambers: the atria and ventricles. This chamber formation involves the growth of septa, partitions that separate the atria from the ventricles and the left ventricle from the right ventricle.

Concurrently, the heart valves, which regulate blood flow through the heart, begin to develop. These valves form from endocardial cushions, specialized structures that originate from the inner lining of the heart. The endocardial cushions undergo a complex process of differentiation, proliferation, and apoptosis, ultimately forming the distinct valve leaflets.

Throughout this intricate process, various signaling pathways are activated, including the Wnt, TGFβ, and Notch pathways. These pathways play crucial roles in regulating cell proliferation, differentiation, migration, and apoptosis, all essential for the proper development of the heart. Moreover, extracellular matrix proteins, such as fibronectin and collagen, provide structural support and guidance for migrating cells.

Finally, the heart matures, with the development of the conduction system that regulates the electrical activity of the heart. This intricate network of specialized cells ensures that the heart beats rhythmically and effectively pumps blood throughout the body.

Disruptions in any of these intricate processes can lead to congenital heart defects, affecting the structure and function of the heart. These defects range from minor abnormalities to life-threatening conditions, emphasizing the critical importance of tight regulation of heart morphogenesis.

In summary, heart morphogenesis is a complex and highly orchestrated process involving the precise control of cell proliferation, differentiation, migration, and apoptosis. It is regulated by an intricate network of signaling pathways and transcription factors, ensuring the proper development of a functional, four-chambered heart.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Smoothened homologA protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835]Homo sapiens (human)

Compounds (15)

CompoundDefinitionClassesRoles
cyclopaminepiperidinesglioma-associated oncogene inhibitor
pd 173955PD 173955: inhibits src family-selective tyrosine kinase; structure in first sourcearyl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine
tyrosine kinase inhibitor
purmorphaminepurmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group.

purmorphamine: structure in first source
aromatic ether;
morpholines;
purines;
secondary amino compound
osteogenesis regulator;
SMO receptor agonist
cur 61414CUR 61414: inhibits the hedehog signaling pathway; structure in first source
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
lde225sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.

sonidegib: specific Smoothened/Smo antagonist
aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activitybenzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamidethioureas
ipi-926IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first sourcepiperidines
gsk 1363089GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first sourcearomatic ether
tak-441TAK-441: structure in first source
ly2940680
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylureaBGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.

infigratinib: structure in first source
aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas
antineoplastic agent;
fibroblast growth factor receptor antagonist
cep-32496agerafenib: inhibitor of RAF family kinases; structure in first source
pf-52748571-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source